This case consult with Drs. Do and Kaiser presents a treatment-experienced patient referred for a second opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). The faculty discuss the recently approved anti-VEGF agents with greater durability and longer dosing intervals that can decrease treatment burden, as well as the treatment responses in this patient and whether to modify dosing intervals or switch therapies.